Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Lawmakers Tepid on Health Issues amid Weak Lobbying Campaigns on Generics, Drug Price Cuts
June 1, 2015
- AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
- MHLW’s Ryukaikon Council to Meet on June 17 to Review Distribution Conditions in FY2014
June 1, 2015
- 12 APIs/15 Products including Lantus Biosimilars Added to NHI Price List
May 29, 2015
- Gilead’s Combination Hep C Drug Likely to Win Japan Approval Late June
May 29, 2015
- Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo
May 28, 2015
- MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015
- MHLW Approves MSD’s Pegintron for Adjuvant Therapy for Malignant Melanoma
May 27, 2015
- MHLW to Set Generic Share Target of 80% by FY2020-End: Shiozaki
May 27, 2015
- MHLW Notifies of Package Insert Change for Plavix
May 27, 2015
- ICH Likely to OK Brazil, China as Assembly Members at Fukuoka Confab
May 26, 2015
- MHLW Grants Orphan Designation for Rituximab, Metirosine
May 26, 2015
- PAFSC 1st Committee to Review Lilly’s GLP-1 Receptor Agonist Dulaglutide on June 5
May 25, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 11 - May 24
May 25, 2015
- Considerable Resolve Needed for Proposed 80% Generic Target: JGA
May 25, 2015
- JSGM President Muto Calls for “Favorable Environment” to Promote Use of Biosimilars
May 25, 2015
- Govt Panel Members Renew Call for Annual Drug Price Cuts, Amari Says Conclusion Out after 2016-2018 Consecutive Revisions
May 20, 2015
- Panel OKs Sovaldi for Medical Subsidy, Monthly Copay at 10,000-20,000 Yen
May 19, 2015
- Generic Drug Use May Reach 60% Target Ahead of Schedule, but Raising Target to 80% Would Be “Difficult”: Director Jo of EAD
May 18, 2015
- PAFSC Second Committee to Review Safety Information of Takeda’s Hib Vaccine on May 28
May 18, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…